Genentech takes aim at Biogen and Novartis, highlighting an early look at positive results for their oral SMA drug from PTC
After getting hit with a setback that forced the pharma giant Roche to abandon its lead drug for spinal muscular atrophy, company execs are back …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
